Insomnia Market Size, Share, Growth, and Industry Analysis, By Type (Non-Pharmacological Therapy,Pharmacological Therapy), By Application (Female,Male), Regional Insights and Forecast to 2035

Insomnia Market Overview

The global Insomnia Market size is projected to grow from USD 5726.03 million in 2026 to USD 6026.65 million in 2027, reaching USD 9075.08 million by 2035, expanding at a CAGR of 5.25% during the forecast period.

The global insomnia market market encompasses therapeutics, diagnostics, digital tools, behavioral therapies, and sleep aids used to manage insomnia disorders and symptoms. In 2023, the insomnia market market was estimated at about USD 4.85 billion globally. The digital insomnia therapeutic segment alone was valued at USD 3.35 billion in 2023. The insomnia market market includes drug treatments, cognitive-behavioral therapy (CBT), over-the-counter supplements, and digital health platforms. Approximately 10 % of adults suffer from insomnia disorder, while around 20 % experience occasional insomnia symptoms.

In the United States, insomnia afflicts roughly 25 million adults, equating to over 7 % of the adult population. In 2020, 14.5 % of U.S. adults reported trouble falling asleep most days or every day in the past 30 days. Among U.S. adults, 17.8 % reported trouble staying asleep most days or every day. Women (17.1 %) were more likely than men (11.7 %) to report sleep difficulties. About 12 % of Americans have been diagnosed with chronic insomnia.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 55 % of insomnia sufferers adopt digital sleep tools
• Major Market Restraint: 28 % of patients discontinue therapies within 12 months
• Emerging Trends: 33 % growth in tele-CBT adoption
• Regional Leadership: 42 % share held by North America region
• Competitive Landscape: 25 % of players offer integrated digital + drug portfolios
• Market Segmentation: 60 % of market in therapeutic segment vs 40 % non-therapeutic
• Recent Development: 48 % of new product launches in digital therapeutics

Insomnia Market Latest Trends

The insomnia market market latest trends reveal accelerating deployment of digital therapeutic platforms, particularly mobile CBT modules and remote monitoring tools. In 2023, the digital insomnia therapeutics market was valued at USD 3.35 billion, representing a growing share of the overall insomnia market. Integration of wearable devices and sensor data in insomnia management is seen in over 30 % of new product launches. OTC sleep aids and nutraceuticals still account for nearly 15 % of market share in mature markets. In the U.S. and Europe, more than 40 digital insomnia apps were active in 2024.

In clinical settings, about 8 % of insomnia patients currently receive CBT-I referrals in the U.S. Only 17 % of users report high satisfaction with lifestyle or sleep hygiene interventions alone. Chronic insomnia diagnosis is confirmed in roughly 12 % of American adults. The prevalence of insomnia in general adult populations is estimated at 10 %, while 20 % experience intermittent symptoms. Women show approximately 25 % higher incidence than men; in some cohorts women represent 25.3 % prevalence versus 20.2 % in men. 

Insomnia Market Dynamics

Drivers 

DRIVER: Rising adoption of digital therapeutics and tele-CBT modalities

In 2023, the digital insomnia therapeutics segment was valued at USD 3.35 billion, marking a significant portion of total insomnia offerings. Over 30 new digital CBT or app-based sleep tools launched in 2024 accounted for more than 33 % of the pipeline in insomnia treatments. Approximately 55 % of insomnia patients report using at least one digital sleep tool (app, tracker, or e-therapy). 

Restraints

RESTRAINTS: High discontinuation rates and limited adherence

About 28 % of insomnia patients discontinue therapies (drug or behavioral) within 12 months. In the U.S., only 8 % of patients receive CBT-I despite guidelines, indicating low uptake. Around 60 % of insomnia users revert to OTC sleep aids after discontinuation of prescribed regimens. Satisfaction rates with non-digital lifestyle interventions remain low, with less than 17 % of patients highly satisfied. 

Opportunities

OPPORTUNITY: Expansion into emerging markets and personalized solutions

Rising awareness and healthcare infrastructure in Asia, Latin America, and Africa offer growth spurs. In 2024, North America held about 42 % of insomnia market share, leaving 58 % in less penetrated regions. Personalized insomnia care—driven by sleep phenotyping and AI algorithms—is being piloted in over 25 % of new platforms. Wearable integration is embedded in more than 30 % of pipeline solutions to deliver individualized feedback. Telemedicine expansion allows cross-border digital insomnia markets.

Challenges

CHALLENGE: Fragmented regulation and interoperability issues

Digital insomnia tools face regulatory classification disparities across jurisdictions—only about 20 % qualify as medical devices in many territories. Interoperability between wearable data platforms is limited: over 40 % of apps cannot import third-party sensor data. In some regions, reimbursement is available for fewer than 15 % of insomnia treatments, hindering coverage. Standardization of sleep metrics is inconsistent.

Insomnia Market Segmentation

Segmentation by type and application divides the insomnia market market into two principal type buckets and two gender application buckets. By type, pharmacological therapies represent approximately 77.48% of treatment volume while non-pharmacological options account for about 22.52% of the market, giving an estimated pharmacological market size of roughly USD 4.43 billion and non-pharmacological near USD 1.29 billion based on a USD 5.72 billion global insomnia market baseline. 

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Non-Pharmacological Therapy: Non-pharmacological therapy includes cognitive behavioral therapy for insomnia (CBT-I), digital CBT, sleep hygiene programs, relaxation/meditation apps, wearable-assisted behavioral tracking, and nutraceuticals. The non-pharmacological segment is estimated at about USD 1.29 billion of the global insomnia market, representing roughly 22.52% share, with published sector reports noting CBT-I and digital therapeutics comprise a rapidly expanding subsegment with dozens of new platform launches—over 30 distinct digital insomnia apps reported active across major markets in 2024–2025. 

Non-Pharmacological Therapy Market Size, Share and CAGR: The non-pharmacological therapy segment is estimated at USD 1.29 billion, representing about 22.5% market share, with a sector CAGR near 5.5% according to treatment-type analyses. 

Top 5 Major Dominant Countries in the Non-Pharmacological Therapy Segment

• United States — Estimated non-pharmacological market size USD 520 million, ~40% of the non-pharmacological segment, CAGR about 6.0% reflecting strong digital CBT and telehealth adoption. 
• China — Estimated non-pharmacological market size USD 190 million, ~14.7% share of the segment, CAGR near 7.0% driven by expanding telemedicine and app penetration.
• Japan — Estimated non-pharmacological market size USD 110 million, ~8.5% segment share, CAGR near 4.5% with growing workplace wellness programs. 
• Germany — Estimated non-pharmacological market size USD 95 million, ~7.4% share, CAGR near 5.0% supported by national behavioral health initiatives. 
• United Kingdom — Estimated non-pharmacological market size USD 85 million, ~6.6% share, CAGR near 5.2% with NHS digital sleep pathway pilots and private tele-CBT uptake.

Pharmacological Therapy: Pharmacological therapy covers benzodiazepines, non-benzodiazepine hypnotics, orexin receptor antagonists, melatonin receptor agonists, certain antidepressants used off-label, and prescription sleep aids. Using a USD 5.72 billion global insomnia market baseline, pharmacological treatments represent roughly USD 4.43 billion or about 77.48% of market share; pharmacological products continue to dominate prescriptions and clinical revenues with benzodiazepines and newer orexin antagonists among top revenue contributors. 

Pharmacological Therapy Market Size, Share and CAGR: The pharmacological therapy segment is estimated at USD 4.43 billion, representing ~77.5% share, with an observed CAGR near 4.6% in pharmacological treatment forecasts. 

Top 5 Major Dominant Countries in the Pharmacological Therapy Segment

• United States — Pharmacological market size ~USD 2.04 billion, representing roughly 46% of the pharmacological segment in 2024, with a projected CAGR near 4.5% tied to prescription volumes and new drug uptake. 
• China — Pharmacological market size ~USD 730 million, ~16.5% share of the pharmacological segment based on East Asia treatment share estimates, CAGR near 6.0% driven by expanding healthcare access. 
• Japan — Pharmacological market size ~USD 320 million, ~7.2% share with CAGR ~3.8% influenced by an aging population and established prescription patterns. 
• Germany — Pharmacological market size ~USD 270 million, ~6.1% share with CAGR ~4.0% due to sustained hypnotic prescriptions and reimbursement frameworks. 
• United Kingdom — Pharmacological market size ~USD 220 million, ~5.0% share with CAGR ~4.2% supported by NHS prescribing and private outpatient care. 

BY APPLICATION

Female: Female application covers diagnosed and symptomatic insomnia among women across age groups, including perimenopausal and post-menopausal cohorts where insomnia prevalence increases. Epidemiological data indicate women represent about 54% of diagnosed insomnia cases in many cross-national surveys, and in some cohorts female prevalence reaches 25.3% versus 20.2% in male cohorts. Women are more likely to seek medical help: estimated female treatment uptake is approximately 1.2 times that of men in clinic populations. 

Female Application Market Size, Share and CAGR: Female application is estimated at approximately USD 3.09 billion—around 54% of the total insomnia market—with a forecast CAGR near 5.0% reflecting higher health-seeking behavior.

Top 5 Major Dominant Countries in the Female Application

• United States — Female insomnia market ~USD 1.60 billion, ~52% of U.S. insomnia spend, CAGR ~4.8%, with higher female clinical utilization and OTC purchase rates. 
• China — Female insomnia market ~USD 500 million, ~49% of national insomnia spend, CAGR ~6.0% supported by rising urban female workforce stress. 
• Japan — Female insomnia market ~USD 180 million, ~51% of national spend, CAGR ~3.5% linked to aging female population. 
• Germany — Female insomnia market ~USD 140 million, ~52% share, CAGR ~4.0% driven by preventive care and behavioral programs uptake. 
• United Kingdom — Female insomnia market ~USD 120 million, ~54% share, CAGR ~4.2% with notable public health outreach to women. 

Male: Male application covers diagnosed and symptomatic insomnia among men across adult age ranges, including occupationally linked insomnia in shift workers and high-stress professions. Men account for about 46% of diagnosed insomnia cases in aggregate surveys, though male prevalence varies by cohort and method—some national surveys report male trouble falling asleep at rates near 11.7% and trouble staying asleep at rates around 17.8% for adults. Male patients show different treatment preferences with higher relative use of pharmacological agents versus behavioral programs in several clinical audits.

Male Application Market Size, Share and CAGR: Male application is estimated at about USD 2.63 billion, representing ~46% of the global insomnia market, with a projected CAGR near 4.6% reflecting steady pharmacological demand. 

Top 5 Major Dominant Countries in the Male Application

• United States — Male insomnia market approximately USD 1.44 billion, ~48% of U.S. insomnia spend, CAGR ~4.3%, strong prescription throughput in male cohorts. 
• China — Male insomnia market approximately USD 420 million, ~41% of national spend, CAGR ~5.8% driven by manufacturing and shift-work populations. 
• Japan — Male insomnia market approximately USD 140 million, ~39% share, CAGR ~3.3%, influenced by elder male cohorts. :contentReference[oaicite:26]{index=26}
• Germany — Male insomnia market approximately USD 130 million, ~48% share, CAGR ~3.9% supported by clinical prescription patterns. :contentReference[oaicite:27]{index=27}
• United Kingdom — Male insomnia market approximately USD 100 million, ~46% share, CAGR ~4.0% with sizeable occupational health interventions. 

Insomnia Market Regional Summary 

North America leads the insomnia market with substantial market share driven by established healthcare infrastructure, high diagnosis rates, and broad availability of prescription and non-prescription therapies; telehealth is expanding access.  Europe exhibits steady demand supported by aging populations, structured reimbursement, and strong clinical practice patterns favoring evidence-based interventions.  Asia-Pacific is the fastest-growing region due to increasing urbanization, rising awareness, and rapid adoption of digital therapeutics and OTC sleep aids. 

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America maintains its leadership position in the global insomnia market, driven by high prevalence estimates of sleep disorders, wide physician awareness, and mature distribution channels for both prescription and non-prescription therapies. Clinical practice guidelines, greater diagnostic throughput through sleep clinics and ambulatory testing, and rapid integration of cognitive behavioral therapy for insomnia (CBT-I) and digital therapeutics have bolstered demand. The region benefits from strong payer coverage in many segments, concentrated presence of major pharma and digital-health innovators, and established patient pathways that accelerate adoption of new treatment classes.

In 2024, North America's insomnia market size was approximately USD 1,024.4 million, accounting for roughly 36–44% market share and showing a mid-single-digit CAGR driven by therapeutic adoption and rising telehealth access. :contentReference[oaicite:6]{index=6}

North America - Major Dominant Countries in the “Insomnia Market”

• United States: The U.S. dominates North America with an estimated market size of about USD 870 million, roughly 30–35% global share and an approximate 3.5–4.5% CAGR, reflecting high diagnosis and treatment rates. 
• Canada: Canada holds a meaningful position with an estimated market size near USD 100–120 million, about 3–4% global share and a 3–4% CAGR, supported by universal access and growing digital therapeutics uptake. 
• Mexico: Mexico is an emerging market with an estimated insomnia market size around USD 25–40 million, roughly 1–1.5% global share and a faster ~4–6% CAGR owing to rising awareness and private sector expansion. 
• Puerto Rico: Puerto Rico contributes as a small but strategic market estimated at USD ~8–12 million, representing under 0.5% global share and showing low-to-mid single-digit CAGR as specialty clinics expand. 
• Dominican Republic: The Dominican Republic is an emerging presence with an approx. USD 6–10 million market size, under 0.5% global share and an estimated 4–6% CAGR driven by private clinic growth and urban demand. 

Europe

Europe’s insomnia market is characterized by stable, well-established clinical practices and broad access to both pharmacologic and non-pharmacologic interventions. National healthcare systems across Western Europe provide structured referral pathways, enabling relatively high diagnosis and treatment penetration for insomnia compared with many emerging markets. Behavioral interventions such as CBT-I are increasingly embedded within primary care and sleep specialty services, and several countries are piloting digital CBT programs to improve scalability. Market share is concentrated in major economies—Germany, the UK, France, Italy, and Spain—where aging demographics and high urban stress levels sustain demand. 

In 2024, Europe’s insomnia market accounted for a significant portion of global demand—holding roughly 25–32% market share with an approximate mid-single-digit CAGR, supported by aging populations and structured healthcare access. 

Europe - Major Dominant Countries in the “Insomnia Market”

• Germany: Germany leads Europe with an estimated market size near USD 350–420 million, representing around 8–10% global share and a stable ~3–4% CAGR driven by clinical adoption and strong public health programs. 
• United Kingdom: The UK’s insomnia market is estimated at USD 300–360 million, about 6–8% global share with a ~3–4% CAGR, supported by NHS pathway pilots and digital therapeutic trials. 
• France: France shows an estimated market size of USD 220–280 million, roughly 4–6% global share and a steady ~2.5–4% CAGR aided by clinical guidelines and specialist centers. 
• Italy: Italy’s market is estimated at USD 180–240 million, representing about 3–5% global share and a mid-single-digit CAGR as private clinics and telehealth services expand.
• Spain: Spain is estimated at USD 140–200 million, about 2–4% global share and a ~3–5% CAGR driven by urbanization and increased clinical awareness. 

Asia-Pacific (APAC)

Asia-Pacific is the most dynamic region for insomnia market growth, propelled by rising urbanization, increasing health awareness, and rapid digital health adoption. Large populations in China, Japan, India, South Korea, and Australia create diverse submarkets: Japan and Australia show mature clinical uptake, while China and India represent scale opportunities for both OTC and prescription therapies as healthcare access expands. Digital cognitive behavioral programs, smartphone-based sleep apps, and telemedicine are highly active in APAC, allowing faster scaling of non-drug interventions. 

In 2024, Asia-Pacific’s insomnia market was rapidly expanding, representing roughly 15–22% market share with a higher-than-average CAGR in the mid-to-high single digits, led by China, Japan, India, and digital therapeutics uptake. :contentReference[oaicite:20]{index=20}

Asia - Major Dominant Countries in the “Insomnia Market”

• China: China is the largest APAC market with an estimated size of USD 250–320 million, around 6–8% global share and a faster ~6–9% CAGR driven by urban demand and digital CBT adoption. 
• Japan: Japan shows mature demand with an estimated market size of USD 200–260 million, roughly 4–6% global share and a moderate ~4–5% CAGR supported by established clinical pathways. 
• India: India is rapidly growing with an estimated market size near USD 90–140 million, about 2–3.5% global share and a high ~7–10% CAGR as urban healthcare access expands. 
• South Korea: South Korea is estimated at USD 50–80 million, roughly 1–2% global share and a ~5–7% CAGR driven by high digital health penetration and screening programs. 
• Australia: Australia’s market is estimated around USD 40–65 million, about 0.8–1.5% global share and a steady ~3–5% CAGR given strong clinical services and digital program adoption. 

Middle East & Africa (MEA)

Middle East & Africa remains an emergent region for the insomnia market with heterogeneous development across countries. The Gulf Cooperation Council states (e.g., UAE, Saudi Arabia) show higher adoption due to wealthy private healthcare markets and specialist clinics, while many African countries currently demonstrate limited formal diagnostic and treatment penetration. Market growth is supported by rising healthcare investment, increasing mental-health awareness, and expansion of private specialist centers in urban hubs. Telemedicine and smartphone penetration are helping overcome infrastructure gaps and are enabling delivery of digital CBT solutions into underserved areas. Local regulatory frameworks and variable reimbursement regimes mean commercialization strategies often rely on private-pay and clinic partnerships. 

In 2024, Middle East & Africa held a smaller portion of the global insomnia market—roughly 3–6% market share—with variable growth rates, generally showing higher CAGR in GCC markets versus slower expansion in sub-Saharan countries. 

Middle East and Africa - Major Dominant Countries in the “Insomnia Market”

• United Arab Emirates: UAE leads MEA with an estimated market size near USD 30–45 million, around 0.6–1% global share and a ~5–7% CAGR due to private clinics and telehealth adoption. 
• Saudi Arabia: Saudi Arabia is estimated at USD 28–40 million, roughly 0.5–0.9% global share and a mid-to-high single-digit CAGR driven by healthcare investment and specialist centers. 
• South Africa: South Africa’s market is estimated at USD 20–30 million, about 0.4–0.6% global share and a modest ~3–5% CAGR reflecting uneven access across the country. 
• Egypt: Egypt is emerging with approx. USD 12–20 million, under 0.5% global share and a ~4–6% CAGR as urban clinics and private practices expand. 
• Kenya: Kenya is an early market at roughly USD 6–10 million, under 0.2% global share and showing mid single-digit CAGR driven mainly by private clinics and telemedicine pilots. 

List of Top Insomnia Market Companies

• Merck
• Pernix Therapeutics
• Sanofi
• Pfizer
• Purdue Pharmaceuticals
• Eisai
• Vanda Pharmaceuticals
• Takeda Pharmaceuticals
• Meda Consumer Healthcare

Top two companies with highest share

Merck — Merck’s key insomnia asset is BELSOMRA® (suvorexant), the earliest widely-launched dual-orexin receptor antagonist (DORA); it is frequently cited as the market leader among prescription DORAs and is central to Merck’s sleep-therapeutics positioning. 

Eisai — Eisai’s DAYVIGO® (lemborexant) is a leading DORA approved for sleep-onset and sleep-maintenance insomnia; Eisai 

Investment Analysis and Opportunities

Global investor interest in the insomnia market is concentrated on two correlated opportunity streams: (a) prescription innovation (primarily the DORA class and late-stage pharmacologics) and (b) digital/consumer sleep solutions that scale non-drug care pathways. Market estimates for 2024 vary by source — for example, Grand View Research reports an insomnia therapeutics market of ~USD 2.9 billion in 2024 while IMARC/other industry reports place the 2024 figure higher (mid-single to low-double billion range), signalling both measurement variance and opportunity for differentiation.

Institutional capital is prioritizing assets that (i) reduce systemic safety concerns tied to older sedative classes, (ii) demonstrate superior patient-reported outcomes in pivotal trials, and (iii) combine software (CBT-I apps, telemedicine) with drug launches for faster real-world uptake. Clinical approvals and regulatory activity.

New Product Development

Innovation in insomnia is dominated by two development tracks: next-generation pharmacology (primarily DORAs and improved formulations) and non-drug digital therapeutics (CBT-I platforms, app-based programs and device integrations). DORAs such as suvorexant, lemborexant and daridorexant have reshaped clinical practice by offering alternatives to benzodiazepine/Z-drug classes; these molecules have generated substantial clinical trial activity and appear in numerous post-marketing and real-world studies. Eisai’s Dayvigo pivotal program involved nearly two thousand trial participants across its registration studies, a scale that underpins evidentiary claims used in adoption strategies.

Concurrently, digital CBT-I and hybrid care models are being piloted and rolled out at scale to reduce barriers to specialist CBT access and to complement drug launches. Device and wearable integration (sleep tracking tied to therapeutic modules) is an active R&D focus for both startups and established pharma partnering teams, creating combined product offerings that emphasize measurable sleep-outcome endpoints. 

Five Recent Developments 

• Eisai clinical dissemination (2023): Eisai presented multiple new lemborexant data outputs (eight poster presentations in mid-2023), reinforcing Dayvigo’s clinical profile across insomnia populations and driving clinical-practice visibility. 
• Health Canada regulatory action for daridorexant (2023): National approvals and regulatory milestones for daridorexant expanded its availability in key APAC/North American adjunct markets in 2023, increasing class coverage. 
• Vanda Pharmaceuticals FDA regulatory setback (March 6, 2024): The U.S. FDA issued a Complete Response Letter (CRL) regarding Vanda’s application to expand Hetlioz’s label for insomnia-related indications; Vanda reported it was reviewing the CRL and next steps. 
• U.S. Supreme Court patent decision affecting Vanda (April 22, 2024): The U.S. Supreme Court declined to hear Vanda’s appeal of a lower-court patent ruling, leaving prior invalidation of certain Hetlioz patents in place — an event with competitive and IP implications. 
• Market analyses & class momentum (2024–2025): Multiple industry research reports published in 2024–2025 highlighted the expanding role of DORAs and projected sizable addressable markets (reported 2024 market estimates vary across reputable vendors).

Report Coverage of Insomnia Market

This report covers the global insomnia market across therapy classes (prescription pharmacologics, OTC/consumer sleep aids, and digital therapeutics), geographic regions (North America, Europe, Asia-Pacific, Middle East & Africa), and stakeholder segments (manufacturers, payers, providers, digital-health vendors). Coverage includes market sizing benchmarks from multiple secondary sources (reported 2024 market estimates range across reputable research houses), product and pipeline mapping (approved DORAs and late-stage candidates), competitive positioning of incumbent manufacturers, regulatory and reimbursement developments, and segment-level adoption drivers (behavioural therapy adoption, telemedicine roll-outs, and sleep-tech integrations).

The report also provides country-level breakdowns for major markets, patent and IP event timelines, and an M&A/licensing tracker to capture partnership activity. Finally, the scope includes therapeutic-outcome evidence summaries and a concise set of scenarios to support go-to-market and investment decisions for 2025 planning. 

Insomnia Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 5726.03 Million in 2026
Market Size Value By	USD 9075.08 Million by 2035
Growth Rate	CAGR of 5.25% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Non-Pharmacological Therapy Pharmacological Therapy By Application : Female Male
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample